Human Fas Ligand/TNFSF6 Standard (人Fas配体 标准品)

FASLG 分子靶点信息概述

• 分子名：FASLG, Fas ligand
• 基因家族：CD molecules; Tumor necrosis factor superfamily; Death inducing signaling complex
• 别名：FasL; CD178
• 曾用名：APT1LG1; TNFSF6
• 全称：tumor necrosis factor (ligand) superfamily, member 6; Fas ligand (TNF superfamily, member 6)

FASLG 分子靶点综述

Fas配体，又名TNFSF6、FasL或CD95L，是肿瘤坏死因子(TNF)家族中的一员。它是一个在细胞毒性T淋巴细胞上表达的同源三聚体II型跨膜蛋白。外基质金属蛋白酶MMP-7在保守裂解位点裂解膜结合的FasL可生成可溶性Fas配体。Fas配体/受体的相互作用在调节免疫系统和癌症的进展中发挥重要作用。它通过FasR的三聚体化产生信号，这个三聚体化通常会导致细胞凋亡或死亡。由Fas-Fas配体结合所引起的凋亡在免疫系统的调节中发挥至关重要的作用，它的功能包括T细胞稳态、细胞毒性T细胞活性、免疫特权、母体耐受性和肿瘤反击。有缺陷的Fas介导的细胞凋亡可导致肿瘤的发生和现有肿瘤的耐药性。Fas基因突变与自身免疫性淋巴增生综合征(ALPS)相关。

人 Human FASLG 分子靶点信息

• 分子名：FASLG, Fas ligand
• 别称：
  • ALPS1B
  • apoptosis (APO-1) antigen ligand 1
  • apoptosis antigen ligand
  • APT1LG1
  • APTL
  • CD178
  • CD95 ligand
  • CD95-L
  • CD95L
  • fas antigen ligand
  • Fas ligand (TNF superfamily, member 6)
  • FASL
  • mutant tumor necrosis factor family member 6
  • TNFSF6
  • TNLG1A
  • tumor necrosis factor (ligand) superfamily, member 6
  • tumor necrosis factor ligand 1A
  • tumor necrosis factor ligand superfamily member 6
• 基因序列：NCBI_Gene: 356
• 蛋白序列：UniProtKB: P48023

人 Human FASLG靶点分子功能（预测）

Predicted to enable signaling receptor binding activity. Involved in several processes, including necroptotic signaling pathway; positive regulation of endothelial cell apoptotic process; and positive regulation of phosphatidylserine exposure on apoptotic cell surface. Acts upstream of or within extrinsic apoptotic signaling pathway via death domain receptors; positive regulation of apoptotic process; and release of sequestered calcium ion into cytosol by endoplasmic reticulum. Located in extracellular exosome; nucleus; and plasma membrane. Implicated in several diseases, including cholangiocarcinoma; chronic myeloid leukemia; pancreatic cancer (multiple); pre-eclampsia (multiple); and type 2 diabetes mellitus. Biomarker of several diseases, including bone marrow cancer (multiple); carcinoma (multiple); cervix uteri carcinoma in situ; clonorchiasis; and neurodegenerative disease (multiple).